Phibro Animal Health (NASDAQ:PAHC) was downgraded by investment analysts at BidaskClub from a “hold” rating to a “sell” rating in a report released on Tuesday.
Several other research firms also recently weighed in on PAHC. Morgan Stanley lifted their target price on shares of Phibro Animal Health from $36.00 to $46.00 and gave the stock an “underweight” rating in a research report on Wednesday, August 29th. Barclays lifted their target price on shares of Phibro Animal Health from $31.00 to $33.00 and gave the stock an “underweight” rating in a research report on Thursday, July 5th. Finally, Zacks Investment Research raised shares of Phibro Animal Health from a “sell” rating to a “buy” rating and set a $53.00 target price on the stock in a research report on Thursday, August 30th. Three research analysts have rated the stock with a sell rating, one has given a hold rating and three have issued a buy rating to the stock. Phibro Animal Health currently has an average rating of “Hold” and an average target price of $43.20.
Phibro Animal Health stock opened at $43.35 on Tuesday. The company has a market capitalization of $1.81 billion, a PE ratio of 24.91, a PEG ratio of 2.59 and a beta of 0.89. The company has a current ratio of 2.90, a quick ratio of 1.66 and a debt-to-equity ratio of 1.62. Phibro Animal Health has a fifty-two week low of $32.05 and a fifty-two week high of $54.62.
Phibro Animal Health (NASDAQ:PAHC) last released its earnings results on Monday, August 27th. The company reported $0.46 earnings per share for the quarter, topping the consensus estimate of $0.42 by $0.04. The business had revenue of $211.80 million for the quarter, compared to the consensus estimate of $209.27 million. Phibro Animal Health had a net margin of 7.90% and a return on equity of 39.81%. The firm’s quarterly revenue was up 8.7% compared to the same quarter last year. During the same period last year, the firm posted $0.39 earnings per share. equities research analysts predict that Phibro Animal Health will post 1.8 earnings per share for the current fiscal year.
In related news, major shareholder Bfi Co., Llc sold 9,470 shares of the business’s stock in a transaction that occurred on Tuesday, July 17th. The shares were sold at an average price of $48.20, for a total transaction of $456,454.00. Following the transaction, the insider now directly owns 47,470 shares of the company’s stock, valued at $2,288,054. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Jack Bendheim sold 10,000 shares of the business’s stock in a transaction that occurred on Wednesday, June 27th. The shares were sold at an average price of $45.79, for a total transaction of $457,900.00. Following the transaction, the chief executive officer now directly owns 60,000 shares in the company, valued at $2,747,400. The disclosure for this sale can be found here. Insiders have sold 383,960 shares of company stock worth $18,474,427 over the last ninety days. 51.88% of the stock is currently owned by insiders.
A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Bank of New York Mellon Corp grew its position in Phibro Animal Health by 3.2% during the second quarter. Bank of New York Mellon Corp now owns 349,574 shares of the company’s stock valued at $16,097,000 after purchasing an additional 10,895 shares in the last quarter. California Public Employees Retirement System grew its position in Phibro Animal Health by 7.6% during the second quarter. California Public Employees Retirement System now owns 38,619 shares of the company’s stock valued at $1,778,000 after purchasing an additional 2,723 shares in the last quarter. Macquarie Group Ltd. grew its position in Phibro Animal Health by 16.3% during the second quarter. Macquarie Group Ltd. now owns 9,998 shares of the company’s stock valued at $460,000 after purchasing an additional 1,400 shares in the last quarter. Cubist Systematic Strategies LLC purchased a new position in Phibro Animal Health during the second quarter valued at approximately $255,000. Finally, Renaissance Technologies LLC grew its position in Phibro Animal Health by 18.2% during the second quarter. Renaissance Technologies LLC now owns 634,500 shares of the company’s stock valued at $29,219,000 after purchasing an additional 97,700 shares in the last quarter. 50.45% of the stock is currently owned by hedge funds and other institutional investors.
Phibro Animal Health Company Profile
Phibro Animal Health Corporation operates as a diversified animal health and mineral nutrition company primarily in the United States. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets products for a range of food animals comprising poultry, swine, beef and dairy cattle, and aquaculture.
See Also: What Is An Exchange-Traded Fund (ETF)?
Receive News & Ratings for Phibro Animal Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Phibro Animal Health and related companies with MarketBeat.com's FREE daily email newsletter.